[1] Hodson, E.M., Knight, J.F., Willis, N.S., Craig, J.C., 2000. Corticosteroid therapy for nephrotic syndrome in children. Arch Dis Child, 83(3):45-51.
[2] Liu, D., Yang, J.W., Chen, Z.H., Dai, C.S., Liu, Z.H., Li, L.S., 1999. Relationship between cell cycle and apoptosis of activated T lymphocyctes induced by triptolide. Chin J Immun, 15(10):455-459.
[3] Mendoia, S.A., Tune, B.M., 1995. Management of the difficult nephrotic patients. Pediatr-Clin-Am, 42:1459-1468.
[4] Qiu, D., Kao, P.N., 2003. Immunosupressive and anti-inflammatory mechanisms of triptolide, the principle active diterpenoid from Chinese medicinal herb Tripterygium Wilfordii Hookf. Drugs RD, 4(1):1-18.
[5] Takcda, A., Takimoto, H., Mizusawa, Y., Simosa, M., 2001. Prediction of subsequent relapse in children with steroid-sensitive nephrotic syndrome. Pediatr-Nephrol, 16:888-893.
[6] Yang, J.Y., 2000. Considerations in clinical diagnosis, treatment and research of nephrotic syndrome. Chin J Pediatr, 38(5):280-281.
[7] Yap, H.K., Han, E.J., Heng, C.K., Gong, W.K., 2001. Risk factors for steroid dependency in children with idiopathic nephrotic syndrome. Pediatr-Nephrol, 16:1049-1052.
Open peer comments: Debate/Discuss/Question/Opinion
<1>